Effects of Remote Ischemic Conditioning on Dynamic Cerebral Autoregulation, Blood Pressure and Heart Rate Variability in Patients With Cerebral Small Vessel Disease

Launched by YI YANG · Jan 25, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called remote ischemic conditioning on patients with cerebral small vessel disease. Cerebral small vessel disease affects the tiny blood vessels in the brain, which can lead to problems like small strokes or other symptoms. The researchers want to find out how this treatment can help improve the way the brain regulates blood flow, as well as how it affects blood pressure and heart rate.

To be eligible for the study, participants must have a diagnosis of cerebral small vessel disease confirmed by brain imaging and be willing to participate. This means anyone, regardless of age or gender, can join as long as they meet these criteria. Participants can expect to undergo some tests and monitoring related to their blood flow and heart function during the study. It's important to note that people with certain medical conditions, such as severe bleeding disorders or previous significant heart issues, may not be able to participate. If you're interested in learning more or participating, please ask your healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Regardless of age, sex;
• * 2) Patients are diagnosed with cerebral small vessel disease, and neuroimaging shows new subcortical lacunar infarction (in line with one of the following):
• • ① MRI examination Diffusion-weighted imaging (DWI) phase shows high signal intensity \[Apparent Diffusion Coefficient (ADC) diffusion restriction\] lesions \< 20 mm diameter in subcortical, basal ganglia or brainstem , with or without corresponding clinical symptoms;
• • ② With new clinical symptoms, MRI examination FLAIR sequence shows corresponding FLAIR high signal intensity lesions \[diameter \< 20 mm\]) in subcortical, basal ganglia or pons;
• • 3) Remote ischemic conditioning can be started within 7 days from onset;
• • 4) Willing to participate and sign the informed consent.
• Exclusion Criteria:
• • 1) Vascular stenosis \> 50% by Transcranial Doppler (TCD);
• • 2) Previous history of intracranial hemorrhage or major bleeding in other parts of the body;
• • 3) Previous history of atrial fibrillation or myocardial infarction within 6 months;
• • 4) Moyamoya disease or hereditary cerebral small vessel disease, such as mitochondrial encephalopathy, CADASIL or Fabry;
• • 5) The patients who had clear non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy;
• • 6) Severe hepatic and renal diseases, cancer or other major diseases related to medical and surgical procedures;
• • 7) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb; Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
• • 8) Significant coagulation abnormalities;
• • 9) Pregnant or lactating women;
• • 10) The patients with disturbance of consciousness or agitation who cannot cooperate to dynamic cerebral autoregulation monitoring or beat-to-beat blood pressure monitoring;
• • 11) Previous remote ischemic conditioning therapy or similar treatment;
• • 12) Unwilling to be followed up or treated for poor compliance;
• • 13) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission;
• • 14) Other conditions that the researchers think are not suitable for the group.